Navigation Links
Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
Date:5/15/2008

GAITHERSBURG, Md., May 15 /PRNewswire/ -- MedImmune today announced that researchers will present eight abstracts from its respiratory disease program at the Annual Meeting of the American Thoracic Society, from May 18 to 20, 2008 in Toronto, Canada. Presentations are designed to showcase MedImmune's biologics capabilities.

"MedImmune is committed to finding innovative solutions that may one day help patients struggling with respiratory diseases," said Tony Coyle, vice president, head, autoimmunity inflammation and respiratory disease research. "We are pleased to present a plethora of promising data that could potentially address diseases such as asthma and chronic obstructive pulmonary disease."

MedImmune research scheduled to be presented includes:

-- Regulation of Lung Inflammation in Animal Models (Poster Session:

IL-33, the Ligand for T1/ST2, Induces Airway Hyperresponsiveness Via a

Mast Cell but Not T Cell Dependent Mechanism, publication page A63)

- Sunday, May 18 from 8:15 a.m.- 4:15 p.m., Metro Toronto Convention

Centre, Area E.

-- Viral Infection and Wheezing (Poster Session: Evidence for T-Lymphocyte

Independent Antibody Responses in Primary RSV Infection, publication

page A190)-Sunday, May 18 from 8:15 a.m. - 4:15 p.m., Metro Toronto

Convention Centre, Area A.

-- Chitins: Flying High (Symposium: Hyperresponsiveness and Inflammation

in a Murine Model of Asthma, publication page A501)- Monday, May 19 at

2:45 p.m., Ontario, Fairmont Royal York Hotel.

-- New Insights and Developing Controversies in Clinical Asthma (Poster

Session: Safety Profile, Pharmacokinetics and Biologic Activity of a

Single IV Dose of the Anti IL-5 Receptor Alpha Antibody MEDI-563 in

Patients with Mild Asthma, publication page A569)-Tuesday, May 20 from

8:15 a.m.- 11:00 a.m., Metro Toronto Convention Centre, Room 20
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
2. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
3. PARI Respiratorys LC PLUS & PRONEB Ultra Deliver Dey, L.P.s New COPD Therapy; Perforomist Launched Yesterday
4. Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement
5. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
6. Retired Supreme Court Justice Sandra Day OConnor and Former House Speaker Newt Gingrich Address Senate Special Committee on Aging, Calling for Urgent Action Against Alzheimers Disease
7. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
8. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
9. Novel Approach to Treat Alzheimers and Other Diseases Offered by Targeting Cell Membrane RAFTS
10. Liver Diseases: A Huge European Health Burden, But Some Trends are Positive
11. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... first quarter 2015 results before the Nasdaq market opens ... a live conference call and webcast to discuss its financial ... 30, 2015 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1906 (US) or 785-424-1825 (International) ...
(Date:4/23/2015)... Calif. , April 23, 2015  Veracyte, Inc. (NASDAQ: ... into a definitive agreement to sell approximately $40 million ... the agreement, the investors will purchase an aggregate of ... of $8.15 per share, the closing stock price on ... new and existing investors, including Broadfin Capital, Camber Capital, ...
(Date:4/23/2015)... HOUSTON , April 23, 2015  Metanome, ... today announced the company has changed its name ... reflect Diversigen,s positioning as the single commercial source ... need to capitalize on the diverse opportunities of ... types that Diversigen accepts – including those that ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 Delpor, Inc. ... announced that the United States Patent and Trademark Office ... NANOPORâ„¢ technology. US Pat. No. 8,986,727 ... microfabricated drug delivery device for the sustained ... NANOPORâ„¢ technology for the sustained (zero-order) release of large ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... 21 Biopure Corporation,(Nasdaq: BPUR ) today announced ... 31, 2008. For the quarter, the company reported a ... compared with a net loss,of $6.9 million, or $0.53 ... A common shares outstanding on January 31, 2008 and ...
... Genmab and PDL BioPharma Have Entered into an Agreement Under, ... ... Brooklyn Park, Minnesota, USA, COPENHAGEN, Denmark and REDWOOD CITY, ... Inc.,(Nasdaq: PDLI ) announced today that they have entered ...
... and PHILADELPHIA, February 21, Shire plc (LSE: SHP, NASDAQ: SHPGY) the global,specialty biopharmaceutical company ... seen significant growth in launched,products., - All $ values are ... ... 41% to $2,170m - Product sales ...
Cached Biology Technology:Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 2Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 3Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 4Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 5Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 6Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 7Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 8Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 9Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 10Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 11Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 12Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 13Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 14Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 15Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 16Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 17Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 18Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 19Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 20Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 21Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 22Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 23Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 24Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 25Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36% 26
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... protein naturally occurring in the brain improves recovery from stroke ... the stroke, and could be used as an effective stroke ... access journal BMC Biology shows that an injection of Granulocyte-Colony ... control the formation of neurons and counteract neurone death, reduces ...
... researchers have identified protein interactions that regulate the response ... could lead to new ways to boost the effectiveness ... cancer drugs. , The study, published online this ... the National Academy of Sciences, also uncorks an almost ...
... that autoimmunity can be triggered in the thymus, where the ... recognize just one of the body's thousands of proteins as ... can start in this cradle of the immune system, and ... as the pancreas in the case of type 1 diabetes, ...
Cached Biology News:Brain protein improves stroke symptoms in rats, even when injected after 3 days 2Researchers find docking sites for glucocorticoid receptor and Hsp90 2Proteins anchor memories in our brain 2Proteins anchor memories in our brain 3
... is a modified cap analog in which ... is replaced with OCH3. Because of this ... transcription with the remaining hydroxyl group thus ... As a result, unlike transcripts synthesized with ...
... called a ?cap? is present on ... mRNAs and many viral RNAs. Substitution ... of the GTP present in an ... the synthesis of transcripts with a ...
... structure called a ?cap? is present ... eukaryotic mRNAs and many viral RNAs. ... portion of the GTP present in ... in the synthesis of transcripts with ...
... A modified nucleotide structure called a ... of most naturally-occurring eukaryotic mRNAs and ... Analog for a portion of the ... transcription reaction results in the synthesis ...
Biology Products: